Share chart Valneva SE
Extended chart
Simple chart
About
Валнева С.Е., компания по производству специализированных вакцин, сосредоточилась на разработке и коммерциализации профилактических вакцин от инфекционных болезней с неудовлетворенными потребностями.
More details| P/S | 1.87 |
|---|---|
| P/BV | 1.75 |
| EV/EBITDA | 25.46 |
| EBITDA | 0.0101 |
| Сайт | https://valneva.com |
| Число акций ао | 0.13862 млрд |
| Цена ао | 2.86 |
| P/E | 76.21 |
| Выручка | 0.1262 |
| Валюта | usd |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | eur |
| Change price per day: | -0% (2.74) |
|---|---|
| Change price per week: | -4.2% (2.86) |
| Change price per month: | -21.49% (3.49) |
| Change price per 3 month: | -25.95% (3.7) |
| Change price per half year: | -28.83% (3.85) |
| Change price per year: | -50.63% (5.55) |
| Change price per 3 year: | -80.41% (13.99) |
| Change price per 5 year: | -29.2% (3.87) |
| Change price per year to date: | -56.16% (6.25) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 801 | 0.58 |
| iShares Core MSCI EAFE ETF | 646 | 0.46 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 371 | 0.27 |
| iShares MSCI EAFE Small Cap ETF | 366 | 0.26 |
| General American Investors Co | 348 | 0.25 |
| Vanguard International Stock Index-Vanguard European Stock Index | 202 | 0.15 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 196 | 0.14 |
| iShares Genomics Immunology and Healthcare ETF | 180 | 0.13 |
| iShares Core MSCI Total International Stock ETF | 169 | 0.12 |
| Vanguard International Stock Index-Total Intl Stock Indx | 1 | 0.98 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Thomas Lingelbach | President, CEO & Director | 996.05k | 1963 (61 year) |
| Mr. Franck Grimaud MBA | Chief Business Officer | 434.73k | 1967 (57 years) |
| Dr. Juan-Carlos Jaramillo M.D. | Chief Medical Officer | 584.65k | 1972 (52 years) |
| Mr. Joshua Drumm Ph.D. | Vice President of Investor Relations | N/A | |
| Ms. Laetitia Bachelot-Fontaine | VP of Global Communications & European Investor Relations | N/A | |
| Mr. Peter Buhler | Chief Financial Officer | 605.32k | 1971 (53 years) |
| Ms. Dipal Patel | Chief Commercial Officer | 559.74k | 1975 (49 years) |
| Mr. Frederic Jacotot | VP of Legal & IP, General Counsel, and Corporate Secretary | 1964 (60 years) | |
| Mr. Vincent Dequenne | Chief Operating Officer | 1967 (57 years) | |
| Dr. Hanneke Schuitemaker Ph.D. | Chief Scientific Officer |
Address: France, Saint-Herblain, 6 rue Alain Bombard - open in Google maps, open in Yandex maps
Website: https://valneva.com
Website: https://valneva.com
